» Articles » PMID: 33409804

Management of Cardiovascular Health in People with Severe Mental Disorders

Overview
Publisher Current Science
Date 2021 Jan 7
PMID 33409804
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: To review evidence regarding the association between bipolar disorder and schizophrenia, henceforth referred to as severe mental disorders (SMD), and cardiovascular morbidity and mortality, its mechanisms, and the interventions to reduce this burden.

Recent Findings: Much of the loss in life expectancy in people with SMD remains driven by cardiovascular mortality. Antipsychotics and mood stabilizers are associated with negative cardio-metabolic outcomes, but large inter-individual differences are observed, and not treating SMD might be associated with even greater cardiovascular mortality. Classical modifiable cardiovascular risk factors remained inadequately screened and, once identified, too seldom treated in people with SMD. After a myocardial infarction, aggressive tertiary prevention may be as effective in people with SMD as in the general population but is less prescribed. Reduced healthcare quality and increased prevalence of cardiovascular risk factors may not fully explain the excess cardiovascular mortality associated with SMDs, which themselves should be considered risk factors in risk calculators. Hazardous health behaviors, the cardio-metabolic adverse effects of medications, and a reduced access to quality healthcare remain priority targets for intervention.

Citing Articles

Excess mortality and its causes among older adults with schizophrenia versus those with bipolar disorder and major depressive disorder: a 5-year prospective multicenter study.

Hoertel N, Sanchez-Rico M, Kassm S, Brami B, Olfson M, Rezaei K Eur Arch Psychiatry Clin Neurosci. 2024; .

PMID: 38294521 DOI: 10.1007/s00406-023-01752-1.


A Cardiovascular Risk Optimization Program in People With Schizophrenia: A Pilot Randomized Controlled Clinical Trial.

Riera-Molist N, Assens-Tauste M, Roura-Poch P, Guimera-Gallent M, Santos-Lopez J, Serra-Millas M J Psychiatr Pract. 2023; 29(6):456-468.

PMID: 37948170 PMC: 10631505. DOI: 10.1097/PRA.0000000000000743.


Schizophrenia as a risk factor for cardiovascular and metabolic health outcomes: a comparative risk assessment.

Ali S, Santomauro D, Ferrari A, Charlson F Epidemiol Psychiatr Sci. 2023; 32:e8.

PMID: 36756905 PMC: 9971851. DOI: 10.1017/S2045796023000045.


Should antidiabetic medicines be considered to reduce cardiometabolic risk in patients with serious mental illness?.

Mc Namara K, Alzubaidi H, Murray M, Samorinha C, Dunbar J, Versace V Med J Aust. 2022; 217 Suppl 7:S29-S33.

PMID: 36183318 PMC: 9828708. DOI: 10.5694/mja2.51701.


Schizophrenia and Hospital Admissions for Cardiovascular Events in a Large Population: The APNA Study.

Guillen-Aguinaga S, Brugos-Larumbe A, Guillen-Aguinaga L, Ortuno F, Guillen-Grima F, Forga L J Cardiovasc Dev Dis. 2022; 9(1).

PMID: 35050235 PMC: 8778060. DOI: 10.3390/jcdd9010025.